California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
ANZ Faces Legal Battle as Former CEO Shayne Elliott Sues Over A$13.5 Million Bonus Dispute 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
Apple App Store Injunction Largely Upheld as Appeals Court Rules on Epic Games Case 
Rio Tinto Signs Interim Agreement With Yinhawangka Aboriginal Group Over Pilbara Mining Operations 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
SpaceX Edges Toward Landmark IPO as Elon Musk Confirms Plans 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
Evercore Reaffirms Alphabet’s Search Dominance as AI Competition Intensifies 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
Heidelberg, Germany, March 14, 2017 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that Dr. Adi Hoess, CEO, will present at the Oppenheimer 27th Annual Healthcare Conference on Tuesday, March 21, 2017 at 4:30 a.m. (ET) in New York.
A live webcast of the conference presentation can be accessed through the "Events" section on the "Media" page of the Affimed website at http://www.affimed.com/events.php. A replay of the presentation will be available from Affimed's website for 30 days following the respective conference.
About Affimed N.V.
Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK- and T-cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.
IR Contact:
Caroline Stewart, Head IR
Phone: +1 347394 6793
E-Mail: [email protected] or [email protected]
Media Contact:
Anca Alexandru, Head of Communications, EU IR
Phone: +49 6221 64793341
E-Mail: [email protected]
